TY - JOUR
T1 - Methods and matrices
T2 - Approaches to identifying miRNAs for Nasopharyngeal carcinoma
AU - Plieskatt, Jordan L.
AU - Rinaldi, Gabriel
AU - Feng, Yanjung
AU - Levine, Paul H.
AU - Easley, Samantha
AU - Martinez, Elizabeth
AU - Hashmi, Salman
AU - Sadeghi, Nader
AU - Brindley, Paul J.
AU - Bethony, Jeffrey M.
AU - Mulvenna, Jason P.
N1 - Funding Information:
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NHMRC. This research was supported by an award from National Health and Medical Research Council, Australia (NHMRC) project grant (#1051627). Expression Analysis, A Quintiles Company (Durham, NC) performed the library preparation and small RNA sequencing. The Agilent microarrays were hybridized and scanned at the Genomics and Epigenomics Shared Resource, Georgetown University Medical Center with the assistance of David Goerlitz.
PY - 2014/1/6
Y1 - 2014/1/6
N2 - Background: Nasopharyngeal carcinoma (NPC) is a solid tumor of the head and neck. Multimodal therapy is highly effective when NPC is detected early. However, due to the location of the tumor and the absence of clinical signs, early detection is difficult, making a biomarker for the early detection of NPC a priority. The dysregulation of small non-coding RNAs (miRNAs) during carcinogenesis is the focus of much current biomarker research. Herein, we examine several miRNA discovery methods using two sample matrices to identify circulating miRNAs (c-miRNAs) associated with NPC.Methods: We tested two miRNA discovery workflows on two sample sources for miRNAs associated with NPC. In the first workflow, we assumed that NPC tumor tissue would be enriched for miRNAs, so we compared miRNA expression in FFPE from NPC cases and controls using microarray and RNA-Seq technologies. Candidate miRNAs from both technologies were verified by qPCR in FFPE and sera from an independent NPC sample set. In a second workflow, we directly interrogated NPC case and control sera by RNA-Seq for c-miRNAs associated with NPC, with candidate c-miRNAs verified by qPCR in the sera from the same independent NPC sample set.Results: Both microarray and RNA-Seq narrowed the miRNA signature to 1-5% of the known mature human miRNAs. Moreover, these two methods produced similar results when applied to the same sample type (FFPE), with RNA-Seq additionally indicating " unknown" miRNAs associated with NPC. However, we found different miRNA profiles in NPC sera compared to FFPE using RNA-Seq, with the few overlapping miRNAs found to be significantly up-regulated in FFPE significantly down-regulated in sera (and vice versa). Despite the different miRNA profiles found in FFPE and sera, both profiles strongly associated with NPC, providing two potential sources for biomarker signatures for NPC.Conclusions: We determined that the direct interrogation of sera by RNA-Seq was the most informative method for identifying a c-miRNA signature associated with NPC. We also showed that there are different miRNA expression profiles associated with NPC for tumor tissue and sera. These results reflect on the methods and meaning of miRNA biomarkers for NPC in tissue and peripheral blood.
AB - Background: Nasopharyngeal carcinoma (NPC) is a solid tumor of the head and neck. Multimodal therapy is highly effective when NPC is detected early. However, due to the location of the tumor and the absence of clinical signs, early detection is difficult, making a biomarker for the early detection of NPC a priority. The dysregulation of small non-coding RNAs (miRNAs) during carcinogenesis is the focus of much current biomarker research. Herein, we examine several miRNA discovery methods using two sample matrices to identify circulating miRNAs (c-miRNAs) associated with NPC.Methods: We tested two miRNA discovery workflows on two sample sources for miRNAs associated with NPC. In the first workflow, we assumed that NPC tumor tissue would be enriched for miRNAs, so we compared miRNA expression in FFPE from NPC cases and controls using microarray and RNA-Seq technologies. Candidate miRNAs from both technologies were verified by qPCR in FFPE and sera from an independent NPC sample set. In a second workflow, we directly interrogated NPC case and control sera by RNA-Seq for c-miRNAs associated with NPC, with candidate c-miRNAs verified by qPCR in the sera from the same independent NPC sample set.Results: Both microarray and RNA-Seq narrowed the miRNA signature to 1-5% of the known mature human miRNAs. Moreover, these two methods produced similar results when applied to the same sample type (FFPE), with RNA-Seq additionally indicating " unknown" miRNAs associated with NPC. However, we found different miRNA profiles in NPC sera compared to FFPE using RNA-Seq, with the few overlapping miRNAs found to be significantly up-regulated in FFPE significantly down-regulated in sera (and vice versa). Despite the different miRNA profiles found in FFPE and sera, both profiles strongly associated with NPC, providing two potential sources for biomarker signatures for NPC.Conclusions: We determined that the direct interrogation of sera by RNA-Seq was the most informative method for identifying a c-miRNA signature associated with NPC. We also showed that there are different miRNA expression profiles associated with NPC for tumor tissue and sera. These results reflect on the methods and meaning of miRNA biomarkers for NPC in tissue and peripheral blood.
KW - Biomarker
KW - Methods
KW - MicroRNAs
KW - Nasopharyngeal carcinoma
KW - Next generation sequencing
KW - qPCR
KW - RNA-Seq
KW - Tumor
KW - Carcinoma
KW - Oligonucleotide Array Sequence Analysis
KW - Nasopharyngeal Neoplasms/blood
KW - Humans
KW - Middle Aged
KW - Gene Expression Regulation, Neoplastic
KW - Male
KW - Malaysia
KW - DNA, Complementary/genetics
KW - Case-Control Studies
KW - Paraffin Embedding
KW - Aged, 80 and over
KW - Female
KW - Tissue Fixation
KW - Real-Time Polymerase Chain Reaction
KW - Herpesvirus 4, Human/genetics
KW - Gene Expression Profiling/methods
KW - Nasopharyngeal Carcinoma
KW - Biomarkers, Tumor/blood
KW - RNA, Viral/genetics
KW - MicroRNAs/blood
KW - Aged
KW - RNA, Neoplasm/genetics
KW - Cluster Analysis
UR - http://www.scopus.com/inward/record.url?scp=84891513445&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-12-3
DO - 10.1186/1479-5876-12-3
M3 - Article
C2 - 24393330
AN - SCOPUS:84891513445
VL - 12
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 3
ER -